2. Search Result
Search Result
Results for "

Eps15 Homology Domain (EHD) Protein

" in MedChemExpress (MCE) Product Catalog:

1636

Inhibitors & Agonists

10

Screening Libraries

8

Fluorescent Dyes

19

Biochemical Assay Reagents

237

Peptides

191

Inhibitory Antibodies

65

Natural
Products

508

Recombinant Proteins

38

Isotope-Labeled Compounds

349

Antibodies

8

Click Chemistry

37

Oligonucleotides

2

GMP Molecules

Targets Recommended:
Cat. No. 상품명 Target 연구분야 Chemical Structure
  • HY-15098
    Apoptozole
    10+ Cited Publications

    Apoptosis Activator VII

    		 HSP Apoptosis Cancer
    Apoptozole (Apoptosis Activator VII) is an inhibitor of the ATPase domain of Hsc70 and Hsp70, with Kds of 0.21 and 0.14 μM, respectively, and can induce apoptosis.
    Apoptozole
  • HY-153992
    STAT6-IN-3
    1 Publications Verification

    		 STAT Inflammation/Immunology
    STAT6-IN-3 is a phosphopeptide mimic targeting the SH2 domain of STAT6 and has a high affinity for STAT6 (IC50: 0.04 μM). STAT6-IN-3 can be used in the research of inflammation such as asthma .
    STAT6-IN-3
  • HY-164607
    YL-5092

    		DNA/RNA Synthesis Apoptosis Cancer
    YL-5092 is a selective YT521-B homology (YTH) domain-containing protein 1 (YTHDC1) inhibitor with an IC50 of 7.4 nM and a KD of 29.6 nM. YL-5092 can suppress cancer cell proliferation and induce cell G0/G1 phase arrest and apoptosis. YL-5092 can be used for the research of cancer, such as acute myeloid leukemia (AML) .
    YL-5092
  • HY-173156
    UNC10013

    		Histone Methyltransferase Cancer
    UNC10013 is an inhibitor targeting the triple Tudor domain (3TD) of SETDB1. UNC10013 covalently binds to Cys385 of SETDB1 3TD, acts as a negative allosteric modulator of the methyltransferase domain of SETDB1, reduces the level of Akt methylation mediated by SETDB1, and blocks Tyr308 phosphorylation of Akt. UNC10013 is applicable to cancer-related research .
    UNC10013
  • HY-141799
    Dimethyl-F-OICR-9429-COOH

    		Ligands for Target Protein for PROTAC WDR5 Cancer
    Dimethyl-F-OICR-9429-COOH a ligand for WD40 repeat domain protein 5 (WDR5) extracted from patent WO2019246570A1 intermediate 19. Dimethyl-F-OICR-9429-COOH can be used in the synthesis of PROTACs .
    Dimethyl-F-OICR-9429-COOH
  • HY-14722
    NVP-BSK805
    3 Publications Verification

    		 JAK Cancer
    NVP-BSK805 is an ATP-competitive JAK2 inhibitor, with IC50s of 0.48 nM, 31.63 nM, 18.68 nM, and 10.76 nM for JAK2 JH1 (JAK homology 1), JAK1 JH1, JAK3 JH1, and TYK2 JH1, respectively .
    NVP-BSK805
  • HY-14722A
    NVP-BSK805 dihydrochloride
    3 Publications Verification

    		 JAK Cancer
    NVP-BSK805 dihydrochloride is an ATP-competitive JAK2 inhibitor, with IC50s of 0.48 nM, 31.63 nM, 18.68 nM, and 10.76 nM for JAK2 JH1 (JAK homology 1), JAK1 JH1, JAK3 JH1, and TYK2 JH1, respectively .
    NVP-BSK805 dihydrochloride
  • HY-12063
    PHT-427
    2 Publications Verification

    		 Akt Apoptosis Cancer
    PHT-247 is an inhibitor of the pleckstrin homology (PH) domain of Akt, and it is also an inhibitor of PDPK1 with Kis of 2.7 µM and 5.2 µM and for Akt and PDPK1, respectively.
    PHT-427
  • HY-P99562
    Tidutamab

    XmAb-18087

    		 CD3 Cancer
    Tidutamab (XmAb-18087) is a humanized and affinity-optimized bispecific antibody (bsAb) targeting SSTR2 binding domain and T-cell binding domain (CD3). Tidutamab possesses a full Fc domain to maintain long serum half-life.Tidutamab eliminates SSTR+ tumor cells by stimulating redirected T cellmediated cytotoxicity (RTcC) .
    Tidutamab
  • HY-117570
    KSC-34

    		PDI Neurological Disease
    KSC-34, a covalent modifier of protein disulfide isomerase A1 (PDIA1), is also a selective and potent a-site inhibitor of PDIA1 with an IC50 of 3.5 μM. KSC-34 displays a 30-fold selectivity for a domain over a′ domain and displays high selectivity for PDIA1 in complex proteomes with minimal engagement of other members of the PDI family . KSC-34 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    KSC-34
  • HY-18377
    Bioymifi
    1 Publications Verification

    DR5 Activator

    		 TNF Receptor Apoptosis Cancer
    Bioymifi (DR5 Activator), a potent TRAIL receptor DR5 activator, binds to the extracellular domain (ECD) of DR5 with a Kd of 1.2 μM. Bioymifi can act as a single agent to induce DR5 clustering and aggregation, leading to apoptosis .
    Bioymifi
  • HY-N2521
    Tetramethylcurcumin

    FLLL31

    		 STAT Apoptosis Inflammation/Immunology Cancer
    Tetramethylcurcumin (FLLL31), derived from curcumin, specifically suppresses the phosphorylation of STAT3 by binding selectively to Janus kinase 2 and the STAT3 Src homology-2 domain. Tetramethylcurcumin exhibits anti-inflammatory and anti-cancer effects .
    Tetramethylcurcumin
  • HY-P3279
    EPQpYEEIPIYL
    1 Publications Verification

    		 Src Cancer
    EPQpYEEIPIYL, a phosphopeptide, is a Src homology 2 (SH2) domain ligand. EPQpYEEIPIYL activates Src family members (e.g. Lck, Hck, Fyn) by binding to SH2 domains .
    EPQpYEEIPIYL
  • HY-138283
    MR837
    1 Publications Verification

    		 Histone Methyltransferase Cancer
    MR837 is an inhibitor of NSD2-PWWP1. MR837 can bind with human nuclear receptor binding SET domain protein 2 (PWWP domain) .
    MR837
  • HY-19977
    YU238259

    		DNA-PK Cancer
    YU238259 is an inhibitor of homology-dependent DNA repair (HDR), used for cancer research.
    YU238259
  • HY-139287
    M1002
    2 Publications Verification

    		 HIF/HIF Prolyl-Hydroxylase Cancer
    M1002 is a hypoxia-inducible factor-2 (HIF-2) agonist, and can enhance the expression of HIF-2 target genes. M1002 shows synergy with prolyl-hydroxylase domain (PHD) inhibitors .
    M1002
  • HY-149935
    OICR-8268

    		Ligands for E3 Ligase Cancer
    OICR-8268 is a reversible DCAF1 ligand that binds to the DCAF1 WDR domain with a Kd of 38 nM. OICR-8268 can enable the development of DCAF1-based PROTACs .
    OICR-8268
  • HY-151577
    STAT3-SH2 domain inhibitor 1

    		STAT Apoptosis Cancer
    STAT3-SH2 domain inhibitor 1 is a potent Src Homology 2 (SH2) Domain of STAT3 (STAT3-SH2 domain) inhibitor with a Kd value of 1.57 μM. STAT3-SH2 domain inhibitor 1 inhibits STAT3 signaling transduction and transcriptional activation. STAT3-SH2 domain inhibitor 1 induces apoptosis in gastric cancer cells. STAT3-SH2 domain inhibitor 1 can be used in research of cancer .
    STAT3-SH2 domain inhibitor 1
  • HY-15369
    FPA-124

    		Akt Apoptosis Cancer
    FPA-124, a cell-permeable copper complex, is a selective Akt inhibitor with an IC50 of 0.1 μM. FPA-124 interacts with both the pleckstrin homology (PH) and the kinase domains of Akt. FPA-124 induces apoptosis .
    FPA-124
  • HY-P10697A
    VH4127 TFA

    		LDLR Metabolic Disease
    VH4127 TFA is a cyclic peptide targeting the low density lipoprotein receptor (LDLR) with a KD of 18 nM for hLDLR. VH4127 TFA specifically binds to rodent and human epidermal growth factor (EGF) homology domain of LDLR .
    VH4127 TFA
  • HY-P10108
    Hexokinase II VDAC binding domain peptide, cell-permeable

    Hxk2VBD peptide, cell-permeable

    		 Hexokinase Neurological Disease
    Hexokinase II VDAC binding domain peptide (Hxk2VBD peptide) is a cell-permeable hexokinase II VDAC binding domain. Hexokinase II VDAC binding domain peptide inhibits mitochondrial localization of hexokinase 2 (HXK2). Hexokinase II VDAC binding domain peptide inhibits neurotrophic factor-directed axon outgrowth .
    Hexokinase II VDAC binding domain peptide, cell-permeable
  • HY-146127A
    Grb2 SH2 domain inhibitor 1 TFA

    		Src Others
    Grb2 SH2 domain inhibitor 1 TFA is a conformationally restricted cyclic cell penetrating peptide (CPP) containing d-pro-l-pro motif ring (AF Φ Rpprrfq) (where Φ It is L-naphthylalanine, R is D-arginine, P is D-proline), which is mainly used as a cyclic peptide inhibitor.
    Grb2 SH2 domain inhibitor 1 TFA
  • HY-RS04452
    EPS15 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    EPS15 Human Pre-designed siRNA Set A contains three designed siRNAs for EPS15 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    EPS15 Human Pre-designed siRNA Set A
    EPS15 Human Pre-designed siRNA Set A
  • HY-146127
    Grb2 SH2 domain inhibitor 1

    		MEK Cancer
    Grb2 SH2 domain inhibitor 1 is an inhibitor of the Grb2 SH2 domain with an IC50 of 0.40 μM. Grb2 SH2 domain inhibitor 1 is also a cell-permeable cyclic peptide that can enter the cytosol of mammalian cells. Grb2 SH2 domain inhibitor 1 downregulates the expression level of p-MEK. Grb2 SH2 domain inhibitor 1 can be used in the research of breast cancer .
    Grb2 SH2 domain inhibitor 1
  • HY-158415
    ATPase-IN-4

    		ATP Synthase EHD Protein Cancer
    ATPase-IN-4 (Compound MS1) inhibits the ATPase activity of EHD4 (IC50: 0.92 μM). ATPase-IN-4 also inhibits EHD2 enzymatic activity
    ATPase-IN-4
  • HY-P4998
    Chemotactic Domain of Elastin

    		Biochemical Assay Reagents Cancer
    Chemotactic Domain of Elastin is an elastin-derived peptide with chemotactic effects on certain tumor cells, such as M27 tumor cells. Chemotactic Domain of Elastin can be used in cancer research .
    Chemotactic Domain of Elastin
  • HY-168929
    SHP1 activator 1

    		SHP1 Fluorescent Dye Phosphatase STAT Apoptosis Cancer
    SHP1 activator 1 (Compound 3n) is an activator for src homology-2 domain-containing protein tyrosine phosphatase 1(SHP1) with an EC50 of 17.66 μM. SHP1 activator 1 inhibits the proliferation of ABC-DLBCL cells, induces apoptosis by inhibiting STAT3 signaling pathway. SHP1 activator 1 emitts blue and green fluorescence signalis in MDA-MB-231 cell, and can be used as a cell imaging agent .
    SHP1 activator 1
  • HY-141539A
    SETDB1-TTD-IN-1 TFA
    5 Publications Verification

    		 Histone Methyltransferase Cancer
    SETDB1-TTD-IN-1 TFA is a potent, selective and endogenous binder competitive ligand of SET domain bifurcated protein 1 tandem tudor domain (SETDB1-TTD) that binds to TTD, with a Kd of 88 nM. SETDB1-TTD-IN-1 TFA increases SETDB1 methyltransferase activity. SETDB1-TTD-IN-1 TFA can be used for the research of biological functions and disease associations of SETDB1-TTD .
    SETDB1-TTD-IN-1 TFA
  • HY-P4933
    Tau Peptide (255-314) (Repeat 2 Domain) (human)

    Tau-F Protein (255-314)

    		 Tau Protein Neurological Disease
    Tau Peptide (255-314) (Repeat 2 Domain) (human) (Tau-F protein (255-314)) is a polypeptide. Tau Peptide (255-314) (human) is the 255-314 fragment of Tau-F (also known as Tau-4, the 2N4 isoform), a major isoform of the Tau protein. Tau Peptide (255-314) (human) contains two core driving sequences for Tau aggregation, namely PHF6* (275-280, VQIINK) and PHF6 (306-311, VQIVYK), and spans the C-terminal half of repeat domain R1, the entire repeat domain R2, and the N-terminal half of repeat domain R3 within the microtubule-binding region (MTBR).
    Tau Peptide (255-314) (Repeat 2 Domain) (human)
  • HY-157332
    WDR5-IN-7

    		WDR5 Cancer
    WDR5-IN-7 (Compound 22) is an orally bioavailable benzoxazepinone-based WD repeat domain 5 (WDR5) inhibitor. WDR5-IN-7 can be used for the research of anti-cancer .
    WDR5-IN-7
  • HY-W010554
    1,4-Cyclohexanedione

    		Drug Intermediate Others
    1,4-Cyclohexanedione is a drug intermediate. 1,4-Cyclohexanedione is an accepted substrate of EryKR1 domain which takes on a certain biocatalyst activity and stereospecificity .
    1,4-Cyclohexanedione
  • HY-135782
    iso-ADP ribose

    		Poly(ADP-ribose) Glycohydrolase (PARG) Cancer
    iso-ADP ribose is the small-molecule ligand for protein nucleic acid modification, comprising parts of two consecutive ADP-ribosyl units within the PAR chain. iso-ADP ribose specifically binds WWE, FHA and OB-fold domains, enabling PAR-dependent functional responses like ubiquitylation and supporting DNA damage signaling and repair. iso-ADP ribose can be used for cancer research .
    iso-ADP ribose
  • HY-RS22489
    Eps15 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Eps15 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Eps15 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Eps15 Mouse Pre-designed siRNA Set A
    Eps15 Mouse Pre-designed siRNA Set A
  • HY-RS29012
    Eps15 Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others
    Eps15 Rat Pre-designed siRNA Set A contains three designed siRNAs for Eps15 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Eps15 Rat Pre-designed siRNA Set A
    Eps15 Rat Pre-designed siRNA Set A
  • HY-169960
    2DII

    		mTOR Cancer
    2DII is a potent and selective mTORC2 inhibitor. 2DII selectively binds mSin1 PH domain and decreases the expression of AKT1 phosphorylation .
    2DII
  • HY-P1195
    PDZ1 Domain inhibitor peptide

    		iGluR Neurological Disease
    PDZ1 Domain inhibitor peptide, a cyclic peptide, incorporates a β-Ala lactam side chain linker and targets the PDZ1 domains of the postsynaptic density protein 95 (PSD-95). PDZ1 Domain inhibitor peptide disrupts the GluR6/PSD-95 interaction and is very efficient in competing against the C terminus of GluR6 for the PDZ1 domain .
    PDZ1 Domain inhibitor peptide
  • HY-159758
    EcDHFR/FKBP12 F36V binder-1

    		Others Neurological Disease Cancer
    EcDHFR/FKBP12 F36V binder-1 (compound 1) is a bifunctional molecule that combines the Escherichia coli dihydrofolate reductase domain (EcDHFR) with the FKBP12 F36V domain .
    EcDHFR/FKBP12 F36V binder-1
  • HY-175343
    OICR-41103

    		Ligands for E3 Ligase Infection
    OICR-41103 is an effective, selective, cell-active DCAF1 small molecule chemical probe that targets the DCAF1 WDR domain and replaces the viral Vpr protein. The binding Ki value of OICR-41103 and DCAF1 is less than 2 nM .
    OICR-41103
  • HY-115383
    Roflupram
    1 Publications Verification

    		 Phosphodiesterase (PDE) Neurological Disease Inflammation/Immunology
    Roflupram is a selective, orally active and brain-penetrant PDE4 inhibitor, with an IC50 of 26.2 nM for core catalytic domains of human PDE4. Roflupram can reverse cognitive deficits and reduce the production of pro-inflammatory factors .
    Roflupram
  • HY-19820
    NSC45586

    		Akt Ser/Thr Protease Neurological Disease Cancer
    NSC45586 is an inhibitor of pleckstrin homology domain and leucine-rich repeat protein phosphatase (PHLPP). NSC45586 targets the PP2C phosphatase domain in PHLPP1 and PHLPP2. NSC45586 can activate AKT in neurons .
    NSC45586
  • HY-128590
    PHT-7.3
    1 Publications Verification

    		 Ras Cancer
    PHT-7.3 is a selective inhibitor of connector enhancer of kinase suppressor of Ras 1 (Cnk1) pleckstrin homology (PH) domain (Kd=4.7 μM). PHT-7.3 inhibits mut-KRas, but not wild-type KRas cancer cell and tumor growth and signaling. PHT-7.3 has antitumor activity .
    PHT-7.3
  • HY-150619
    KDM4-IN-4

    		Histone Demethylase Cancer
    KDM4-IN-4 (compound 47) is a potent histone lysine demethylase 4 (KDM4) inhibitor with a modest affinity binding to ~80 μM for KDM4A-Tudor domain. KDM4-IN-4 can inhibit H3K4Me3 binding to the Tudor domain in cells with an EC50 value of 105 μM. KDM4-IN-4 can be used for researching anticancer .
    KDM4-IN-4
  • HY-P2516
    Tau Peptide (275-305) (Repeat 2 domain)

    		Tau Protein Neurological Disease
    Tau Peptide (275-305) (Repeat 2 domain) is the Alzheimer's Tau fragment R2, corresponding to the second repeat unit of the microtubule-binding domain, which is believed to be pivotal to the biochemical properties of full tau protein. Tau Peptide (275-305) specifically coordinates with group IIB metal ions (Zn²⁺, Cd²⁺, Hg²⁺), which can induce their conformational changes and significantly promote their pathological accumulation. Tau Peptide (275-305) can be used to study the role of heavy metals in neurodegenerative diseases .
    Tau Peptide (275-305) (Repeat 2 domain)
  • HY-110013
    Terreic acid

    		Btk Antibiotic Infection Inflammation/Immunology
    Terreic acid, a quinone epoxide antibiotic, acts as an effective Btk inhibitor. Terreic acid blocks the interaction between PKC and the pleckstrin homology domain of Btk. Terreic acid inhibits the binding of GST-BtkPH to PKC in lysates of HMC-1 human mast cells with an IC50 of approximately 100 μM .
    Terreic acid
  • HY-P1816
    Fibronectin CS1 Peptide

    		Integrin Cancer
    The connecting segment 1 (CS-1) is a cell attachment domain located in the type III homology connecting segment (IIICS) of fibronectin. Fibronectin CS1 Peptide lacks the Arg-Gly-Asp-containing domain, actively inhibits tumor metastases in spontaneous and experimental metastasis models .
    Fibronectin CS1 Peptide
  • HY-P10697
    VH4127

    		LDLR Metabolic Disease
    VH4127 is a cyclic peptide targeting the low density lipoprotein receptor (LDLR) with a KD of 18 nM for hLDLR. VH4127, bearing non-natural amino acid residues, specifically binds to rodent and human epidermal growth factor (EGF) homology domain of LDLR .
    VH4127
  • HY-RS04453
    EPS15L1 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    EPS15L1 Human Pre-designed siRNA Set A contains three designed siRNAs for EPS15L1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    EPS15L1 Human Pre-designed siRNA Set A
    EPS15L1 Human Pre-designed siRNA Set A
  • HY-P4968
    Tau Peptide (337-368) (Repeat 4 Domain)

    		Tau Protein Others
    Tau Peptide (337-368) (Repeat 4 Domain) is a 32-amino acid peptide derived from the fourth microtubule-binding repeat sequence (R4) of the tau protein. Tau Peptide (337-368) (Repeat 4 Domain) can be used in research on neurodegenerative diseases .
    Tau Peptide (337-368) (Repeat 4 Domain)
  • HY-155019
    Anticancer agent 128

    		IAP Cancer
    Anticancer agent 128 (compound 1) is an IAP inhibitor that covalently targets the BIR3 domains of XIAP, cIAP1, and cIAP2. Anticancer agent 128 targets the BIR3 domains of XIAP, cIAP1, and cIAP2 with IC50s of 24.9 nM, 19.3 nM, and 10.3 nM, respectively .
    Anticancer agent 128
  • HY-155018
    Anticancer agent 127

    		IAP Cancer
    Anticancer agent 127 (142D6) is an IAP inhibitor that covalently targets the BIR3 domains of XIAP, cIAP1, and cIAP2. Anticancer agent 127 targets the BIR3 domains of XIAP, cIAP1, and cIAP2 with IC50s of 12 nM, 14 nM, and 9 nM, respectively. Anticancer agent 127 has anticancer effects .
    Anticancer agent 127

온라인 문의

Your information is safe with us. * Required Fields.

호칭

  

Country or Region *

고객명 *

 

회사명 *

Department *

     

메일주소 *

 

상품명 *

Cat. No.

  

Requested quantity *

전화번호 *

     

비고

온라인 문의

Inquiry Information

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent: